ABSTRACT
The effects of two antifungal compounds, the azole itraconazole and the allylamine terbinafine, on Leishmania major infections in mice are reported. Sixty BALB/c mice were each inoculated subcutaneously with metacyclic promastigotes of L. major at the base of the tail. From 4 weeks post-inoculation, 40 of the mice were treated for 4 weeks (20 with itraconazole and 20 with terbinafine) and the rest were left untreated. Lesion sizes were estimated weekly for 10 weeks post-infection. Both drugs appeared effective in treating the cutaneous lesions but response to itraconazole was faster and, at the end of the experiment, the mean size of the lesions on the mice treated with itraconazole was smaller than that of the lesions on the terbinafine-treated mice.
Subject(s)
Antifungal Agents/therapeutic use , Itraconazole/therapeutic use , Leishmania major/drug effects , Leishmaniasis, Cutaneous/drug therapy , Naphthalenes/therapeutic use , Animals , Mice , Mice, Inbred BALB C , Terbinafine , Treatment OutcomeABSTRACT
In a series of 124 patients admitted to hospital with liver disease, 23 (18.6%) had malignant liver disease, either primary or secondary; 12 (9.7%) had cirrhosis of the liver, while another 25 (20.2%) had inflammatory liver disease, including such parasitic infections as hydatid disease and schistosomiasis. The remaining biopsies showed non-specific changes or normal livers.